about
Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activityProgestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cellsTwo domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cellsCDC2 mediates progestin initiated endometrial stromal cell proliferation: a PR signaling to gene expression independently of its binding to chromatin.Pyicos: a versatile toolkit for the analysis of high-throughput sequencing dataThe Dynamic Regulatory Genome of Capsaspora and the Origin of Animal Multicellularity.The progesterone receptor/estradiol receptor association and the progestin-triggered S-phase entry.CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells.Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase trackingChromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways.Erk signaling and chromatin remodeling in MMTV promoter activation by progestins.Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells.Minireview: role of kinases and chromatin remodeling in progesterone signaling to chromatin.More help than hindrance: nucleosomes aid transcriptional regulation.Role of PRC2-associated factors in stem cells and disease.ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia.Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms.Distinct structural transitions of chromatin topological domains correlate with coordinated hormone-induced gene regulation.Progesterone receptor interaction with chromatin.Progesterone receptor induces bcl-x expression through intragenic binding sites favoring RNA polymerase II elongation.Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.Nucleosome-driven transcription factor binding and gene regulation.Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation.Convergence on chromatin of non-genomic and genomic pathways of hormone signaling.Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells.Induction of Progesterone Target Genes Requires Activation of Erk and Msk Kinases and Phosphorylation of Histone H3Progesterone signaling in breast and endometriumPolycomb Regulates NF-κB Signaling in Cancer through miRNADifferential lytic and agglutinating activity of the anti-Lewis x monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studiesReactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasiasMarker Expression and Differentiation in Human Breast CancerThe expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancerDNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cellsThe expression of progesterone receptors coincides with an arrest of DNA synthesis in human breast cancerDNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells
P50
Q24301878-342CB3E0-A494-41EE-A991-D9DBCED33234Q28578038-21D41EBB-2910-4ECD-BC56-0AEAFCDBFED6Q28771752-64988455-6E9A-46ED-913E-CEF103C50057Q33654819-1A97862C-3CF2-41BE-969F-3C2AFA9B2223Q34047461-DD9B2765-E6CC-4287-B22A-E2C0CE74FEF7Q34523527-F47314FF-F158-410C-95EA-FB6E42A5BA82Q36037231-A0575344-2B63-4045-B7E2-6ACE5D085466Q36213722-916AEA2B-121D-4EAC-B0A1-37AA3A8DC690Q36711259-D666957C-C8D3-4250-B053-6342C69C61CDQ36721725-DA9DEDB7-7388-4DBE-AD82-AA1CC35622BBQ37678197-A5CECCB7-D9D6-46E5-9682-AC38A95D5FC8Q37687555-222E68FA-53C9-4CE8-867E-4EC366AC2A9EQ37756419-104B4A33-6857-499F-903D-FEE2EFE29AFFQ38113645-4195047E-BAC3-4929-A385-B60B094AEB60Q38255769-991D8F5C-D3F2-4EF4-B8E8-DCD3667FD1C0Q38310769-B1F7770A-9C5D-4BEF-8F91-3FD243987609Q38355746-5892034B-6E50-42DC-AAAA-32FB40E07646Q38951482-C5ABC87D-633E-4574-80A7-37554859CF7DQ38960363-014FAB40-4D1F-4BB5-A0F3-64E4C45486DFQ39156822-CF7CDC33-7512-4B03-88E3-2C4916D59690Q39162952-C07F9681-9A5E-4D78-8DB9-C21FDF85CCE9Q39239873-9E07BC80-753E-4AF1-93E1-4CE7148EB7BAQ39568693-074AF6A5-8F2A-40D3-BA9D-9D8A95D5FCAAQ39991335-B567B487-F72C-4C31-9729-45DC11F9172BQ41329532-9F047911-89DD-48E7-B271-A98458158AA8Q53844443-8620FE3B-275C-4383-B541-AC8268BB37D6Q53844444-63FC8194-E4DF-4AFF-B245-BDA6715C6634Q57188641-01650F27-54DD-4172-AFCE-4E91371DEB72Q60191841-FA487E15-2B97-4D4A-AD72-871254B5307AQ60191842-2FCCFF62-F978-46F8-9669-8C8D14B55107Q60191843-B3F5BF20-B537-4115-BFD2-E195AAB2CCF0Q60191844-2B37F2E4-0096-4D3F-86EC-C1C68B60DB8BQ60191845-186C69C4-CB1E-4224-8999-56CB4942DC83Q60191846-9C78A4EE-B9D9-4FE9-BD99-EAED168F7926Q68189584-AB7BBA8B-59D9-40DA-9679-291B217F0F68Q69648513-CCC315EF-CEBF-4B75-A766-B8D81C1CEE2B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cecilia Ballaré
@ast
Cecilia Ballaré
@en
Cecilia Ballaré
@es
Cecilia Ballaré
@nl
Cecilia Ballaré
@sl
type
label
Cecilia Ballaré
@ast
Cecilia Ballaré
@en
Cecilia Ballaré
@es
Cecilia Ballaré
@nl
Cecilia Ballaré
@sl
prefLabel
Cecilia Ballaré
@ast
Cecilia Ballaré
@en
Cecilia Ballaré
@es
Cecilia Ballaré
@nl
Cecilia Ballaré
@sl
P1053
F-2593-2016
P106
P21
P31
P3829
P496
0000-0002-9442-807X